a privately held specialty aesthetics company pioneering the development of differentiated medical skincare products based on the science of glycoproteins, announced today the close of a $5 million Series C

This content is restricted to registered user. If you are an existing user, please log in. New users may register for free.

New User Registration
 
 
 
 
 
 
Please indicate that you agree to the Terms of Service *
*Required field